Q4 2022 CVS Health Corp Earnings Call
Speaker 1: and Chief Executive Officer of CDS, Sean Gerton, Executive Vice President and Chief Financial Officer of CDS, and Mike Pekos, Chairman, CEO and co-founder of Oak Street Health.
Speaker 2: we will use non- GAAP measures when talking about the company's performance and financial condition. And you can find a reconciliation of these non- GAAP measures in this morning's press release. And the reconciliation document posted to the Investor Relations portion of our website.
Speaker 3: With that, I'd like to turn the call over to Karen. Karen?
Speaker 4: Thank you Tom and good morning everyone and thanks for joining our call today. This morning we are going to discuss our 2022 results, our 2023 guidance and our announcement that we entered into a definitive agreement to acquire Oak Street Health. Mike Eichos, Chairman CEO and co-founder.
Speaker 5: and we brought a greater value to the people that we serve.
Speaker 6: This morning we announced that we exceeded our adjusted EPS expectations for the fourth quarter in a row, delivering fourth quarter 2022 adjusted EPS of $1.99 and full year 2022 adjusted EPS of $8.69.
Speaker 7: This result represents nearly 10% growth over our 2021 baseline.
Speaker 8: For 2023, we continue to expect adjusted EPS and the range of $8.70 to $8.90, which at the midpoint represents high single digit growth of our 2022 baseline of approximately $8.25 inch
Speaker 9: In 2022, CBS Health surpassed the $300 billion mark in total revenue, growing full-year revenues by more than 10% to $322 billion. We delivered adjusted operating income of $17.5 billion and generated adjusted EPS.
Speaker 10: of $8.69. Our ability to generate cash flow from operations was robust at nearly $16.2 billion for the full year.
Speaker 11: Each of our foundational businesses generated excellent results. Starting with the healthcare benefits segment, we grew revenues by more than 11% for the year and delivered adjusted operating income of $6 billion.
Speaker 12: Our medical benefit ratio of 84% improved by 100 basis points versus the prior year and was consistent with our full year expectations after adjusting for the impact of elevated flow in a fourth quarter.
Speaker 13: I want to highlight a few areas within the HZD segment.
Speaker 14: Although our individual Medicare Advantage growth was below our expectations, Medicare Advantage remains a key strategic growth area for CVS Health. We remain focused on delivering superior service to our Medicare Advantage members while advancing our efforts to improve our star ratings.
Speaker 15: We are executing on the actions we identify to address our CAHP survey scores and are making the necessary investment to drive our staff's improvement initiatives.
Speaker 16: We also made progress in the last 90 days in advancing our efforts to diversify our national PPO contract and have obtained the necessary regulatory approval to move forward. This will enable us to more effectively manage our Medicare business in the future. As we will discuss shortly, adding both Signify Health and Oak Street Health to our value-based care plan.
Speaker 17: network, market growth, market-based disruptions, and our co-branded integrated benefit offerings. We anticipate a positive, sustainable contribution from this membership in future years.
Speaker 18: Our pharmacy services segment grew full-year revenues by 11% with adjusted operating income of $7.4 billion. Performance in our specialty pharmacy was again outstanding. Revenue grew more than 19% year over year driven by our industry-leading digital and specialty pharmacy case of those.
Speaker 19: branded products. Our approach to biosimilars reflects our commitment to drive the lowest net cost for our clients while providing members coverage of clinically safe, effective medications and ensuring continuity of care.
Speaker 20: Retail delivered another strong year, outperforming our initial guidance and long-term targets. Revenues for the year grew by more than 6% versus the prior year, and we generated $6.7 billion of adjusted operating income.
Speaker 21: We finished 2022 with another quarter of strong performance in both the pharmacy and the front store. Pharmacy revenue increased by nearly 8% versus the prior year and delivered another quarter of year-over-year market share games. Front store revenues grew by nearly 7%.
Speaker 22: driven by demand for consumer health and cost, cold, and flu products.
Speaker 23: We are making significant progress advancing our strategy, which includes expanding our care delivery and health services capabilities in primary care, home health, and provider enablement. Last year we announced the pending acquisition of Signify Health.
Speaker 24: which represented an important step forward in our value-based care strategy. Signify will strengthen our presence in the home and enhance our provider enablement capabilities. We now project that this transaction will close in the second quarter of 2023.
Speaker 25: At our investor day in 2021, we shared our vision to deliver a superior health experience for consumers.
Speaker 26: Central to our strategy is advancing our value-based care platform of capabilities that drive consumer engagement.
Speaker 27: This morning, we announced that we have entered into a definitive agreement to acquire Oak Street House outstanding shares for $39 per share in cash, representing a total transaction value of approximately $10.6 billion.
Speaker 28: The acquisition of Oak Street Health will broaden our value-based care platform into primary care and accelerate our long-term growth. Primary care drives patient engagement and positive clinical outcomes. Although it is a very small proportion of total health spend, it is also a very small proportion of total health spend.
Speaker 29: Just about 10% nationally, it wields significant influence over health care utilization. Individuals who seek routine primary care services report fewer serious medical diagnoses, lower mortality rates, and a 33% lower annual health care expense.
Speaker 30: Oak Street Health has a proven senior focused primary care model that is scalable at a national level. Their innovative care model goes beyond typical primary care to provide patients with comprehensive preventative care to support overall health and well-being.
Speaker 31: with 169 medical centers across 21 states today. We see a significant opportunity to expand in the next few years and provide superior care to many more patients.
Speaker 32: Oak Street has a committed and experienced leadership team with expensive care delivery expertise and a best-in-class fully integrated technology solution.
Oak Street's model focuses on providing more coordinated, holistic and connected care.
Oxygen emissions spend three times longer on average with their 159,000 at-risk patients and drive markedly better outcomes.
There are approximately 600 providers and 6,000 team members have a proven ability to improve patient outcomes and experiences.
At a time when consumers are increasingly frustrated with their experience in the health care system, Oak Street's approach delivers a truly specialized care experience that drives a net promoter score of 90.
The quality of this experience is evidenced by the fact that Oak Street was selected to be the trusted primary care partner of AARP and is the only primary care provider to carry the AARP name across all their sites.
As part of CBSL, we believe Oak Street's value-based care model will have a far greater impact on patients. Our unparalleled consumer touch points will expand Oak Street's reach and will allow them to engage with more consumers more frequently and more conveniently.
The combination of CVS Health's foundational businesses with Oak Street and Signify Health creates one of the premier, multi-payer, Medicare value-based care platforms in the marketplace today.
But our ambition does not stop there. These Medicare-focused assets complement our established care delivery assets, including our over 1,100 retail health minute clinics in a number of ways.
creating convenient access and additional clinical capacity for Oak Street with preventive care and chronic care services for seniors.
Enhancing access to our broad nurse practitioner work force.
and providing wraparound services tailored to seniors and those with complex conditions such as medication reconciliation and post-discharge follow-ups.
The potential across CVS Health's base of assets is powerful. Together, we will transform the experience for consumers across the country.
The Oak Street transaction is financially attractive and enhances our ability to accelerate our sustainable long-term growth.
Sean will provide more details on the financials of the transaction and we'll discuss the growth and profitability prospects of the Oak Street assets.
At the close of the transaction, Mike Pico will continue to lead Oak Street within CVSL. Mike we're so excited to welcome you and your team to CVSL at the close of this transaction. Mike would you like to say a few words?
Thank you, Karen. I think I'm going to go more to everyone.
Our mission is to help. It's to rebuild healthcare. Should be.
When we started Oak Street, we set out to address the root cause of high cost, low quality care, and poor experiences for Medicare patients.
10 years in the attorney, as we continue to drive our national expansion and look to impact more patients and communities, we cannot have found a partner more line to our mission than CVSL.
At Oak Street Health, we operate a network of primary care centers to specialize in care for older adults.
We focus on areas with large concentrations of medical eligible patients with incomes below 300% of the federal poverty line.
areas where we can make the biggest impact.
We create our innovative model from the ground up.
and focus on ensuring our patients receive the right care out front, improving their experiences, and keeping them healthy and out of the hospital.
This proven and nationally scalable model of benefits patients, providers and payers, while improving health outcomes, lowering that across and delivering a better patient experience.
This focus is generating meaningful results for our patients, including reducing hospital emissions by over 50 percent and lowering third-day reinmission by 42 percent.
By providing coordinated, holistic care, we can close care gaps and address social determinants of health, delivering five-star heaters performance.
Our traffic shows that we've been able to deliver consistent performance across different populations and geographies.
And while primary focus is Medicare and Angehat risk patient, we've also demonstrated our care molecule work outside of May.
For example, in 2021, we participated in the Medicare Drug Contracting Program, where we took on full risk on traditional Medicare patients.
Among all the participants in the program, we generated savings that were two times higher than any other multi-stage direct contract entity, and we were ranked number one in that dollar state.
These results show that even amongst the most innovative proofs in this new program, our caseability results stood out.
by joining CVS to help with ecosystem.
We will accelerate our journey to improve patient outcomes and experiences while long as to keep the best in both our innovative care model and that's what we believe is the best team in healthcare.
The expansive consumer touchpoint of CVS health virtually and in the community, including the trust of CVS pharmacists, will broaden the deep in our connections with the patients under our care.
At Oak Street, we've talked with the massive market opportunity for companies like him dressed as huge challenges in healthcare.
CVS Healthers' unique position to deliver market leading health solutions. The breadth of their offerings, improvementability to scale assets will significantly enhance our budget tackling challenges.
We believe this transaction is an great outcome for all of our stakeholders, including our patients, all of our parent partners, our two vocies and our shareholders.
With that, let me turn it back to care.
Thank you, Mike.
CDFL delivered strong financial results in 2022, and we are entering 2023 with tremendous momentum. We continue to make progress on our strategy and will enhance the capabilities of our value-based care platform through the Oak Street Health and Signify Health acquisitions. We are excited about the opportunities ahead of us.
I'll turn it over to Sean for a deeper look at our into our results, our 2023 outlook and the Oak Street transaction. Sean?
Thank you, Karen, and good morning, everyone. I will first take some time to detail our results in 2023 guidance before discussing this morning's announcement of the Oak Street transaction.
Our fourth quarter results reflect the continuation of our excellent performance from each of our core business segments as we exceeded our expectations for revenue, cash flow generation in adjusted earnings per share.
A few highlights regarding total company performance.
Total fourth quarter revenues of $8.8 billion increased by 9.5% year over year, reflecting growth at or above internal expectations for each of our foundational businesses.
We reported fourth quarter adjusted operating income of 4 billion and adjusted EPS of $1.99.
For FILLYER 2022, we reported total revenue of $322.5 billion, and increase of 10.4% with solid growth across each of our foundational businesses.
This led to a full year adjusted EPS of $8.69.
representing an increase of 9.7% off our 2021 adjusted EPS baseline of $7.92.
Importantly, CVS helps ability to generate cash remain strong.
For full year 2022, we generated 16.2 billion in cash flow from operations.
Looking at performance by business segment.
Health care benefits delivered strong revenue and adjusted operating income growth versus the prior year.
Fourth quarter revenue of 23 billion increased by 11.3% year over year.
We grew membership by 548,000 lives in 2022.
driven by strong growth in our commercial and Medicare businesses.
Offsetting the divestiture of a portion of our ethnic international business earlier this year, ended decline in Medicaid membership due to a previously disclosed contract loss.
Our medical benefit ratio of 86% improved 100 basis points year over year.
Adjusted operating income of $858 million through 68.2% year-over-year.
Both of these measures were driven by the net favorable impact of COVID-19 compared to the prior year and strong underlying performance.
partially offset by the unfavorable impact of the flu.
Outside of an elevated flu season, medical costs remain in line with expectations as has been the case throughout 2022.
Consolidated days claims payable at the end of the quarter was 52.5 up 3.4 days versus the prior year.
Overall, we remain confident in the adequacy of our reserves.
In the Pharmacy Services business, our ability to deliver industry-leading drug trend for our clients.
Our specialty management capabilities and excellent customer service levels continue to drive growth.
During the fourth quarter, revenue of $43.7 billion increased by 11.2% year-over-year, driven by increased pharmacy claims volume, growth in specialty pharmacy and brand inflation, partially offset by continued client price improvements.
Total pharmacy claims process increased by 3.1% above the prior year and 4.6% when excluding COVID-19 vaccinations.
primarily attributable to net new business, increased utilization, and the impact of an elevated cough, cold, and flu season.
Adjusted operating income of $2 billion grew 9% year over year, driven by improved purchasing economics, including increased contributions from the products and services of the company's group purchasing organization, partially offset by continued client price improvements.
In our retail long-term care segment, we delivered strong revenue growth despite mixed COVID-related trends and continued economic uncertainty.
Specifically, during the fourth quarter, revenue of $28.2 billion grew 4 percent, reflecting increased prescription and front store volume, including the impact of an elevated cough, cold and flu season, pharmacy drug mix and brand inflation.
These items were partially offset by decreased COVID-19 vaccinations and diagnostic testing.
the impact of recent generic introductions and continued pharmacy reimbursement pressure.
Adjusted operating income of 1.8 billion declined 25.1% versus prior year, but was largely in line with internal expectations.
driven by decreased COVID-19 vaccinations and diagnostic testing.
continued pharmacy reimbursement pressure, and increased investments in the segments operations and capabilities, including the vast majority of a discretionary bonus payment to frontline colleagues.
These decreases were partially offset by increased prescription volume in improved generic drug purchasing.
Pharmacy prescription volume grew 0.8 percent year over year, reflecting increased utilization in the impact of an elevated cough, cold, and flu season, partially offset by decreases in COVID-19 vaccinations.
Excluding the impact of COVID-19 vaccinations,
Pharmacy prescription volume increased by 4 percent year over year.
Turning to the balance sheet.
Our liquidity and capital position remain excellent.
We ended the year with approximately 5.4 billion of cash at the parent or unrestricted subsidiaries.
and an adjusted net debt to EBITDA of about 2.9 times.
Excluding the adjustment for cash at the parent or unrestricted subsidiaries, our adjusted debt to EBITDA is approximately 3.1 times.
To our quarterly dividend, we return 719 million to shareholders and repurchase 1.5 billion of our common stock in the fourth quarter.
We also entered into a $2 billion fixed-dollar accelerated share repurchase transaction, which became effective on January 3, 2023.
A few other items worth highlighting for investors.
We continue to experience the impact of market volatility on our investment portfolio and recorded net realized capital losses of approximately $37 million in the quarter.
We recorded 117 million of office real estate optimization charges in the quarter related to the reduction of corporate office real estate space in response to our new flexible work arrangement.
We also recognized a $250 million gain related to the sale of our BeSwift business in November .
And we recorded 99 million of incremental charges related to opioid litigation to address the final terms and other implications of the global settlement executed in December .
Shifting to our outlook for 2023.
We expect revenue growth of 3 to 5 percent, and we are reaffirming our full-year adjusted earnings per share guidance range of $8.70 to $8.90.
We believe this range is prudent at this stage in the year and reflects approximately 5 to 8 percent growth versus our 2022 adjusted ETS baseline of $8.25.
We detailed the adjustments reflected in our 2022 baseline in the earnings materials posted on our IR website.
I want to point out three things on our 2023 Adjusted EPS guidance.
First, consistent with past practice.
Our projections do not assume the recurrence of prior year reserve development.
Second.
These projections do not include a specific provision for our pending Signify transaction.
which is expected to close in the second quarter of this year.
but which we project will have a small impact on 2023 adjusted EPS.
And third, I want to remind everyone that beginning this year, we are shifting to a reporting convention that excludes net realized capital gains and losses from adjusted operating income.
Now let's turn to some of the segment details.
In our healthcare benefits segment, we expect to see membership growth of 2 to 4 percent.
with increased membership in both Medicare and commercial.
partially offset by declines and Medicaid due to the impact of redeterminations in 2023.
Overall, we expect to generate revenue growth of 11 to 13%.
Our projected medical benefit ratio for 2023 is 84.7% plus or minus 50 basis points.
As I just noted, we do not assume prior year reserve development in our projections.
We are providing a cautious outlook for HCB-adjusted operating income, expecting growth in a range of about 2-4%.
and reflecting a prudent assumption regarding the performance of our individual exchange business.
lower individual MA enrollment, and investments in our STARS Improvement Initiatives.
Moving to our pharmacy services segment.
We expect revenue and a range from 1 to 2% growth driven by a successful 2023 selling season in strong retention.
partially offset by lower Medicaid volume.
For the full year 2023, we expect pharmacy claims to range from flat to growth of 1%.
Overall, we expect these results to generate adjusted operating income growth of 4 to 5%.
Finally, shifting to our retail LTC segment.
As we discussed previously, this segment will be burdened by the lower contribution from COVID as we transition into the endemic stage as well as continued reimbursement pressure in the pharmacy.
We expect revenue growth of 1 to 3 percent.
and prescription growth of 2 to 4 percent, despite continuing decreases of COVID-19 vaccines.
Overall, for the retail LTC segment, we expect 2023 adjusted operating income to decline from 2022 to between $5.95 and $6.05 billion.
For items below adjusted operating income, we expect our interest expense for 2023 to be approximately $2.23 billion.
Our tax rate is expected to be approximately 25.5%.
I want to make a few comments as you think about the cadence of our earnings throughout the year as retail returns to earnings seasonality more aligned to pre-pandemic patterns.
We are currently projecting the lowest contribution to earnings in the first quarter of the year.
The remaining three quarters will be relatively consistent, but slightly more than half of our earnings coming in the second half of the year.
shifting to shares
We expect our deluded weighted average share count to be approximately 1.298 billion reflecting the impact of both our fourth quarter 2022 Repurchase Activity as well as the accelerated sharey purchase that is currently underway.
We anticipate another strong year of cash generation.
We expect cash flow from operations of 12.5 to 13.5 billion.
Capital expenditures are expected to be in the range of $2.8 to $3 billion.
Turning to the Oak Street Transaction.
We committed to investors that we would be diligent when deploying our capital.
seeking assets with the best technology, capabilities, and cultural alignment to our vision.
After a thorough and robust review of the market.
Oak Street was the primary care asset that proved to be the most strategically and financially Demonstratetake g honoring of Mel Agenteand shelf
Oak Street will operate as a payer agnostic business within CVS Health.
focused on improving outcomes and experiences for the Medicare populations it serves.
CBS Health has a strong and proven track record of helping its payer clients succeed, and we will continue to prioritize that success after this transaction.
What we saw when we looked into Oak Street's portfolio of clinics was a remarkably consistent path to clinic profitability.
This trend was true across diverse geographies, populations, and payers.
As Oak Street drives strong patient experiences and engagement, their patient panels grow.
And as Oak Street providers engage with those patients, they improve outcomes and increase patient contributions over time.
These two factors combine to drive clinics to maturity.
achieving profitability within the first three years in unlocking annual adjusted EBITDA potential of approximately seven million per clinic using Oak Street's definition of adjusted EBITDA.
Within the 169 clinics Oak Street has today, we have high visibility into embedded adjusted EBITDA of over 1 billion.
We also recognize the tremendous opportunity to scale Oak Street's clanks to reach more seniors across the nation.
At their current rate of expansion, we expect Oak Street to have over 300 clinics by 2026.
At which point we project they will have more than two billion of embedded Oak Street adjusted shutter in the back and
shifting to synergies.
We envision five main opportunities to realize more than 500 million of value over time.
One, accelerating oak street patient growth to receive the S-HELP channels.
2
improving Oak Street's economics through integration with our broad portfolio of assets.
economics through integration with our broad portfolio of assets.
improving the retention of our Aetna MA members through the improved outcomes and experience provided at Oak Street Clinics.
Four, driving greater utilization of CVS Pharmacy and Caremark capabilities. And five, capturing modest savings from external public company and lease costs.
We project that our investment in Oak Street will drive double digit returns on invested capital over time as clinics mature and synergies are realized.
We are committed to exploring additional avenues to further accelerate growth.
energy realization and returns from this transaction while balancing further near-term dilution to our EPS trajectory.
As stated in our press release, this transaction will be funded with available resources in existing financing capacity.
And we remain committed to maintaining our current investment grade rating.
The transaction is subject to approval by Oak Street shareholders.
regulatory approvals and other customary closing conditions.
We expect this transaction to close in 2023.
We are now targeting 2024 adjusted EPS of approximately $9.
growing to approximately $10 in 2025 with the potential for upside in 2025 based on the successful resolution of our Medicare Star ratings mitigation efforts.
The 2024 and 2025 adjusted EPS trajectories reflect the impact of the previously disclosed 2024 Medicare Star ratings headwind in fencing contract loss.
closing of the Oak Street health transaction in 2023, as well as projected contributions from the Signify Health transaction in 2024 and beyond.
Consistent with past practice, CVS Health expects to exclude integration and transaction costs from its adjusted EPS presentation.
With the close of these transactions, we expect that our adjusted debt to EBITDA will peak in the mid-3 times level in 2024.
Well, within leverage ranges aligned to our current investment grade rating.
Our current projections assume modest discretionary repurchase activity in 2024.
This is consistent with our 2021 investor day projections, which contemplated 1-2% adjusted EPS growth from repurchases, in addition to offsetting dilution.
As leverage begins to subside in 2025, we will have potential for additional repurchases.
In summary, we are excited to announce the acquisition of Oak Street and to incorporate them into our expanding portfolio of capabilities.
Oak Street's best in-class clinics will serve as the focal point of high-quality care for seniors across America.
The strategic rationale for this combination is sound and the growth opportunity is most authorized.
together.
CVS Health Foundation or Businesses.
that signifies home assessment and provider enablement capabilities, and Oak Street's Clinics and Care Model create the premier multi-payer Medicare value-based care platform.
We could not be more pleased to join with Oak Street.
as we take the next step in our journey to build a differentiated health services organization in transform how care is delivered.
To conclude.
We delivered excellent performance in 2022, creating strong momentum as we continue to execute our strategy in 2023.
We are building on our achievements, expanding our portfolio of capabilities, and continuing on our path to become the leading healthcare solution company.
With that, we will now open the line for your questions. Operator?
Thank you. At this time, if you wish to ask a question, please press star 1 on your telephone keypad.
You may remove yourself from the queue by pressing star 2. In the interest of time, we ask that you please limit yourself to one question and one quick follow-up.
We'll take our first question from Alicia Gill with JP Morgan. Your line is open.
Thanks very much and congratulations on the transaction and congratulations on the strategy overall. I know every quarter I've asked about the strategy around value-based care and what you're going to do in this area. So I'm happy that you finally have done this. So really just two things I want to better understand. One.
following Oak Street. They did slow the growth of the number of centers they were opening last year to the cash constraints. Um, it sounds like you're laying out that you're going to keep that strategy the same at roughly 35 centers per year. One is there a reason why you wouldn't re accelerate that growth when we think about Oak Street.
And then secondly, you know, as we think about some of the changes that have come with RADB, the MA rates that have come out, can you maybe just talk about the impact not just on the MA side but also on the provider side and did you take that into account when you were thinking about buying a primary care asset?
Okay, Lisa, I'll turn it to Sean in a second, but I just wanted to acknowledge your point about we did lay out a variable vision in December of 2021 to really expand into health services, and I really believe this transaction is a clear win for both patients and providers.
As we said in our prepared remarks, this really does create the premier multi-payer Medicare value-based platform. And you and I talked a lot about value-based care not just being a contract but being a platform where we really drive engagement and connect patients to care. This transaction combined with Signify Health.
really does demonstrate that we are executing on our long-term strategy to drive long-term growth for the company. Let me turn it over to Sean to answer your specific questions. Hi Lisa, so I'm the first one about kind of clinic expansion to be clear the numbers we cited today in our model are prime
accelerating synergy realization, but potentially looking at the growth aspect of that. And in particular, you know, avenues that would help us manage sort of the greater clinic growth, but also sort of manage kind of inside the delusion framework that we've talked about, you know, with this transaction. And we will be looking at those avenues because...
that we've seen in the past and. It's a very important point because when you look at the long term returns of this model, um that accelerated growth has some has some real long term kind of return benefits to doing that. So again, that will be something that we continue to work on and explore the best way to do that within the framework that
We've had the ability to do that and obviously as you all know, much of that still leaves many questions to be answered in the future. It does provide a little bit more clarity than we had in the past. But I think we do understand the dynamics and some of the mitigation efforts that we could put in place of certain things.
When you have a year, for example, when reimbursements get squeezed, what's one of the things you want to do? You want to look at your cost control levers. And certainly, Oak is a demonstrable asset that has proven to improve outcomes and reduce costs.
And so I think as we think about navigating the future of Medicare Advantage and maybe even a broader opportunity in Medicare value-based care in the fee for service population, I think both signify an oak or exactly the kind of assets that you would like to have your side as you do that.
And Lisa, just adding to that point, I think we all recognize the importance of Medicare Advantage and the popularity and we were very encouraged by the political statements that were made last night to support Medicare and this fits really nicely into that picture as well. Great. Thanks so much. Thank you.
Thank you. Our next question will come from Michael Cherney with Bank of America. Your line is open.
Good morning. Thanks for taking the question. Congratulations on the deal. I'm sure there are going to be a number of other questions there. So I want to hone in on health care benefits particularly the work you're doing around stars. I know last month Karen you outlined the waiver and the requirements to push forward on the 24 mitigation plans. Just give us a sense of where you stand on the various different.
workstreams tied to achieving the 25 mitigation and the planned throughput you have in order to get there and re-establish your STARS presence.
Yeah, Mike, thanks for the question. And you're right, we did make progress on our regulatory approvals to move our contracts forward. And we are continuing to make investments in STARS so that we can mitigate the risk. As you might remember, we narrowly missed in our cap scores.
The team has been working very diligently over the course of the last few couple months to make sure that we are improving our results. I'm going to ask Dan to talk about the specifics. Thanks, Karen. So in 2022, we really took a look at the opportunity around Cats and Member Experience and we launched some additional campaign.
that worked really hard with our retail colleagues on in the fourth quarter related to patient medication adherence. And then, of course, on the HEDIS front, closing as many gaps in care as possible in the fourth quarter, and now currently focused on really optimizing our record collection during the hybrid season. So, you know, we're committed to improve our STARS ratings. We believe we have the right actions and the right team to really improve.
Congratulations on the transaction as well. I wondered since we had Mike on the call, the...
Obviously this has played out a little bit in the public domain, so there's been speculation that something might be up with those three for a while. I wonder if he's comment on what kind of feedback he's gotten from his doctors, how are they reacting to this? And I wonder, do they have to approve in any way this transaction? Is there anything in there?
process. You know, it's a little uncertain that it was a few years ago. I guess the way to describe it. If it were to slip into some point in 24, would you, would that material really change your $9 and $10 target?
Are you, does that have some flexibility around timing of the field? Hi, AJ. You know, we do expect to have this transaction closed. I'll let Sean comment on the financials, but I don't think that we have material changes in those numbers.
I want to turn it over to Mike. Mike, can you just respond to AJ's question around the clinicians?
Yeah, happy to. So on the second point, no, we don't require any separate approvals. We just need more of the standard shareholder approvals. On the first question you asked, I think it's the most important one, you know, should help our mission to rebuild healthcare that should be. And I think the positions I've talked to and I'm pretty leaders and team members across those two that I've had a chance to talk to so far.
huge amount of resources that we can partner with and leverage to help us provide higher quality care for patients to help us provide a better patient experience and to help continue make those dreams the best place to work in healthcare. So I think from our physicians and the rest of our team members perspective, I think this is a huge positive.
to continue to help us execute on our mission. Okay, that's great. And, AJ, I'm not sure if you had a question about more global kind of deal returns, but specifically to your question about the timing of close, the answer is no, it would not change those. And arguably, it actually adds a little bit of lift because we remember there's an operating loss.
that's going on for a little bit of time, and you're picking that up a little bit deeper into the cycle of moving from, you know, kind of loss to break even to gain. So, you know, it actually would not kind of change the $9 to $10 at all, certainly not in a negative way.
Okay, great. Thanks a lot. Thank you. Our next question will come from Justin Lake with Wolf Research. Your line is open.
Thanks, good morning. Wanted to shift back to health benefits for a minute. Wanted to ask you people, walk us through your expectations on membership growth across the businesses in detail. So where do you expect to grow in MA, shrink into commercial and then the exchanges?
And then your MLR looks like it's up about 100 basis points. Here we're going to get a little less. Just colorful, you could frame how much of that comes from the PYD roll off that you're not assuming and what other drivers might be impacting that. Appreciate it.
Hey Justin, it's Karen. Let me just comment on the growth. First of all, in our commercial book, you know, we do expect to grow in our commercial book. And our value proposition is truly resonating in the marketplace. We announced, you know, last month that we closed the state of North Carolina, which will bring us about 570,000 members on 1125.
advantage growth, but we are growing our DSNP business and our group MA business. So I'll let Dan specifically give you a little bit more details on growth. But I'm going to turn it to Sean to answer your MBR question. Yeah, so Justin, the MBR, I think the guy's midpoint is up about 70 base.
provision we are making for the exchange business and the provision for any adverse deviation there is also worth about 20 basis points.
about 10 basis points is driven by Medicaid redeterminations and what we think the NBR impact will be there. The divestiture of our international business in 2022, that was lower NBR, so that's adding about 10. So it's three or four items that are building that up. You know, I would say.
still feel the pricing environment is very sound and rational going into 2023.
And Karen, I would just add two comments to your remarks. I mean, first on the Medicare front, a couple of bright spots during AEP were growth in the dual population, as well as our group MA products. And so we expect continued growth in those products through the remainder of the year.
And clearly, the team is also focused on our individual MA enrollment as it relates to OEP and our lock-in period. Some of the investments we made at the end of AEP showed some signs of growth that we're looking forward to for the remainder of the year. And then the last comment would just be on Medicaid. We do expect some modest growth in that book of business through the first quarter.
But as anticipated, at the end of the first quarter, we do expect some of the redetermined members to fall off the roster. And so we're looking at working closely with the states around our opportunities to regain that membership.
Thank you. Our next question will come from Eric Porture with an F-ron research. Your line is open.
Thank you, Eric Pritchard and Josh Raskin here at NIFON. Question with respect to the approach to M&A, how important was geographic diversification in your process or as you're examining assets and making this decision?
And then conversely, how important was homogeneity of the model that Oak Street has built?
And maybe lastly, how do you think about how this and Signify come together with respect to physician enablement?
I can have Karen talk about that as well at the end, but what I would say is as we talked about, you know, our factors here, Eric, you know, we've conducted a very thorough evaluation over the last 15 months and are confident this is the best asset in the space that really satisfied them.
different payers.
It also has, as Mike mentioned, a demonstrable capability to improve clinical outcomes and lower costs and I think a very clear path around the unit economics required for profitability. I'd be remiss if I didn't also mention that it has a fundamentally differentiated patient experience as evidenced by their 90 NPS.
in their exclusive AARP endorsement. So this asset really, we talked about the list of criteria. We really hit it. And I think to your point,
The geography was important, we're a big company, we're going to need a big footprint over time, and being in 21 states was important in and of itself. But it is actually, in my mind, the scalability element was the ability to demonstrate the model worked in different geographies into the point of your second question about.
having, I'll call it the homogeneity of the model, it was the ability to reproduce it.
and then make changes to it. I think that was very, very important and frankly very distinct in what we looked at in the market. I think the second part of your question, I think is important too because there is a lot of interplay potentially down the road between these two assets.
One of, I think, the benefits that we have, and I think we've built in a modest synergy when we talk about the ability to accelerate growth, is the ability of Signify, when they're doing a home visit, to recognize that here is a member that needs to be returned or connected to care.
And that doesn't have to be, obviously, through oak, but a candy, now. And it can be our miniclinics as well. So the interconnectivity of actually getting these members the care they need, when they need it, and where they need it, and to Mike's point, the way it should be provided, I think these two things over time will be able to work powerfully together.
of signifying, oh, but then you think about our minute clinics and we can kind of leverage those minute clinics for additional capacity. We can, you know, we can leverage our nurse practitioners as well and then we can have wraparound services. So we can have a...
very much of a holistic approach to care in the community. I'd also add that it is really critically important for us to be a multi-payer agnostic provider and to make sure that we're connecting care for all the patients that we're interacting with in the community. Thank you.
holistic approach to care in the community. I'd also add that it is really critically important for us to be a multi-payer, you know, agnostic provider and you'll make sure that we're connecting care for all the patients that we're interacting with in the community. Thank you. Thank you.
Thank you. Our next question will come from Steven Baxter with Wells Fargo. Your line is open.
Hi, thanks. I appreciate all the color on the Oak Street acquisition. I was hoping you could help us think a little bit about the timing you'd expect to be required to realize both the greater than 2 billion of earnings power itself and also the $500 million of synergies and also maybe any insight into where both those figures might be on a reported basis over the next couple of years would be great. Thank you.
So let me talk kind of about this in sort of a financial terms and try to get at some of those points.
As I mentioned, we do think this is a deal that has an attractive long-term return on capital, but it also has the potential to move the needle from an earnings perspective in a company of this size and scale.
You know, our strategy has been and will continue to be to deploy capital to improve the sustainable earnings growth rate of this company as a whole. When you look at this asset in concert with Signify, we project this to improve our overall long-term earnings company growth rate by at least 100 basis points a year as these investments mature.
It's important as you think about this that the dilution, especially the dilution from financing, is temporal and short-term, but these sustainable improvements in growth rate are not.
from a return on capital standpoint.
We think it earns double digit returns on capital in year seven and very importantly, because of the embedded value in that clinic infrastructure, that return on capital continues to grow on the order of 200 basis points a year thereafter. And I mentioned in my remarks.
that at the current rate of expansion, we would expect to have 300 clinics.
by the end of 2026. And using the Oak Street convention around adjusted EBITDA at 7 million per clinic, we think the embedded EBITDA could cross the 2 billion threshold in the 2026 year. So that's an important sort of data point, but I think it's important to recognize.
position as a company. And I do think it's important in fact I think being overly slavish to deals that only satisfy short-term returns are exactly what can lead to long-term growth problems. And I think you know we're this is something that has a lot of long-term growth earnings power. And finally you had asked about the synergies.
and some of the kind of accretion dilution. You know, the synergies are powerful here, and I think it's one of the things that we're uniquely positioned to deliver on. I've often when I've talked to all of these companies, they've often said to me, like, if I say, what do you need to grow faster? And they say members and capital. Well, that's something we can bring to bear here.
But most of the synergies, probably about 70% of what we talked about, are tied up really in that accelerated growth and the improved retention of MA members. And so when you think about the model here, the J curve, if you will, this is about moving them along that curve faster. And in that –
trajectory that generally gets closer to breakeven and positive in that year two to three time frame. So that it's after that that a lot of these synergies mature.
The way we see that playing out is I think this would be roughly EPS neutral probably in like year four of our ownership are thereabouts and begin to be accretive on an EPS line for year five but make no mistake it is improving each year which is going to help our growth
between then and now, and you're building substantial embedded long-term value in that footprint.
Thank you.
Our next question will come from Anne Hines with NISDO Securities. Your line is open.
Hi, good morning. Maybe we can shift to retail. Your guidance for OP of $595 to $696. Can you just let us know how much endemic COVID you have in that guidance? And for 2024 and 2025 expectations, are you assuming that stays flat or is there any growth in that business? Thanks.
No, so and for for 2023 we have about 500 to 600 million of what I'll call the endemic COVID contribution from the three categories we've been talking about vaccine diagnostic testing and over-the-counter testing. It's important to recognize that that is significantly down.
from the contribution that we experienced in 2022, nearly a billion dollars down from that. So we're targeting producing the 6 billion again, despite kind of that headwind. In our forecasting, the general, I would tell you the general targeting is we continue to expect retail to be able to maintain flat.
And we have a declining COVID contribution in our thinking behind that, that obviously there's other initiatives. And I can let Michelle and Prem maybe talk about some of the other things that are going on in both the front of the store and the back of the store that are helping the business broadly, but also helping us sort of manage through the decline in COVID contribution.
penetration and we actually grew service levels and that promoter scores that historically high levels and so the foundation and momentum has been strong in the front store this is coming about because of things like our investments in omni-channel modernizing our store fleet improving our merch mix improving service and even our pricing promotional strategy so
This is a kind of underlying momentum and foundation that we think will help us continue our growth trajectory. But at the same time we absolutely recognize there's also opportunity to invest in cost structure and productivity improvements. So we're investing in supply chain for instance to optimize, modernize and selectively automate. We believe that will bear a significant return.
We're also finding lots of other opportunities to improve inventory turns and reduce overall product loss. So it's this combination of growth alongside productivity improvements that we think will continue to fuel our performance. That's just in 2023, but beyond. So let me turn it over to Prem.
Just a couple other points. Our Q4 market share in pharmacy is now approximately 27% of the group share. Another 12 basis points and we're about 117 basis points higher than the pre-pandemic share. And then secondly, I'd say there's two areas we're really focused. One is on our digital approach in our pharmacies and how we continue to be the most convenient.
retail destinations for our patients and consumers and really connecting that with our digital strategies. And the second is really around our clinical programs. We're seeing continued strong adoption of those clinical programs that drive further adherence and retention for our patients. And we're starting to see new therapies also arise.
you know, continued strong momentum in retail from a pharmacy perspective. We continue to have extremely strong service levels in our business as well to drive the business forward.
Thank you. Our next question will come from Nathan Rich with Goldman Sachs. Your line is open.
Hi, good morning. Thanks for the questions. Oak Street's cohort data paints a pretty compelling path just in terms of the embedded EBITDA that is in the centers. I guess what you see is the key variables to kind of achieving that kind of J curve that they've laid out. And you've talked about some of this, but what can CVS do to potentially accelerate the EBITDA?
know, de-loveraging your debt pay down across those years as well. Thank you.
Yeah, so, you know, as you mentioned, I think, and I can certainly, I think, you know, Mike can comment as well, right? Really, the variable, and it's remarkably consistent right over time, is the ability to drive membership growth sort of along to your point along that sort of J curve of cohort.
the infrastructure that we have to do to help with the multi-payer asset. There's obviously things we can do. Um you know, for planned design offerings to highlight the oak network or the old clinics. We can do that with the members. I mentioned signify before as a potential sort of source of members. But when you just think about the vast array of members that we
I think that'll make that offering not only more attractive than the Merz, but all of the payers who contract with Oak. They will all benefit from what we bring to bear with our retail health strategy and our pharmacy strategy and I think that
You know, that is sort of that is an opportunity there. On capital deployment, I think as I mentioned, what we expect to, for this to play out is that, you know, over the next couple of years, we will likely be in the mid-
over the next two to three years after this transaction. Our current projections are, let me step back, as you mentioned, we have a modest amount of share repurchase in the 24, 25. Think about that as maybe a point or two above dilution.
That's very consistent with what we told you on investor day. So when we think about the flexibility we have you know I would say that we would have probably between.
the flexibility. You know, four in a billion of flexibility over the 23 24 window, and then that grows more to like the 10 to 15 billion of flexibility in the 24 25 window timing, obviously, you know, still to be determined, but. I think
because this is the capital that we could continue to use to return value to shareholders via the dividend, obviously incremental share repurchases, deliveraging to your point, or could be used for other corporate purposes.
So, before we conclude, I want to take this opportunity to thank our CVS health colleagues for their extraordinary work bringing our vision to life, improving the health of our customers and delivering on our financial objectives. As you heard today, CVS Health delivered strong results and we're advancing our strategic initiatives.
We entered 2023 with great momentum and we are well positioned for growth in our foundational businesses and we are making continued progress against our strategy. We are so excited about the opportunities ahead of us including both the Signifying Oak Street Health Acquisitions and we look forward to keeping you updated throughout the year. Thank you.
Ladies and gentlemen, this does conclude today's CVS Health fourth quarter and school year 2022 earnings call and webcast. You may disconnect your line at this time and have a wonderful day.
Was per ation.